Literature DB >> 9832350

Inhibition of platelet MAO-B by kava pyrone-enriched extract from Piper methysticum Forster (kava-kava).

R Uebelhack1, L Franke, H J Schewe.   

Abstract

Kava-kava, a psychoactive beverage, induces relaxation, improves social interaction, promotes sleep and plays an important role in the sociocultural life in the islands of the South Pacific. On the other hand, standardized extracts of kava-kava roots are used for the therapy of anxiety, tension and restlessness. Kava pyrones, the major constituents of kava kava, are generally considered to be responsible for the pharmacological activity in humans and animals. To obtain more information on the mechanisms by which kava-kava exerts psychotropic properties we investigated the in vitro effects of kava-kava extract and pure synthetic kava pyrones on human platelet MAO-B, in comparison to amitriptyline, imipramine and brofaromine. Kava-kava extract was found to be a reversible inhibitor of MAO-B in intact platelets (IC50 24 microM) and disrupted platelet homogenates (IC50 1.2 microM). Structural differences of kava pyrones resulted in a different potency of MAO-B inhibition. The order of potency was desmethoxyyangonin > (+/-)-methysticin > yangonin > (+/-)-dihydromethysticin > (+/-)- dihydrokavain > (+/-)-kavain. The two most potent kava pyrones, desmethoxyyangonin and (+/-)-methysticin displayed a competetive inhibition pattern with mean Ki 0.28 microM and 1.14 microM respectively. The inhibition of MAO-B by kava pyrone-enriched extracts might be an important mechanism for their psychotropic activity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9832350     DOI: 10.1055/s-2007-979325

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  13 in total

Review 1.  Plant-based medicines for anxiety disorders, part 2: a review of clinical studies with supporting preclinical evidence.

Authors:  Jerome Sarris; Erica McIntyre; David A Camfield
Journal:  CNS Drugs       Date:  2013-04       Impact factor: 5.749

2.  The Impact of One-week Dietary Supplementation with Kava on Biomarkers of Tobacco Use and Nitrosamine-based Carcinogenesis Risk among Active Smokers.

Authors:  Yi Wang; Sreekanth C Narayanapillai; Katelyn M Tessier; Lori G Strayer; Pramod Upadhyaya; Qi Hu; Rick Kingston; Ramzi G Salloum; Junxuan Lu; Stephen S Hecht; Dorothy K Hatsukami; Naomi Fujioka; Chengguo Xing
Journal:  Cancer Prev Res (Phila)       Date:  2020-02-26

Review 3.  Therapeutic potential of kava in the treatment of anxiety disorders.

Authors:  Yadhu N Singh; Nirbhay N Singh
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

4.  Peripheral serotonergic markers in acutely suicidal patients. 1. Comparison of serotonergic platelet measures between suicidal individuals, nonsuicidal patients with major depression and healthy subjects.

Authors:  J Roggenbach; B Müller-Oerlinghausen; L Franke; R Uebelhack; S Blank; B Ahrens
Journal:  J Neural Transm (Vienna)       Date:  2006-09-21       Impact factor: 3.575

Review 5.  Roles of selected non-P450 human oxidoreductase enzymes in protective and toxic effects of chemicals: review and compilation of reactions.

Authors:  Slobodan P Rendić; Rachel D Crouch; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2022-06-01       Impact factor: 6.168

6.  In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions.

Authors:  S Flanagan; K Bartizal; S L Minassian; E Fang; P Prokocimer
Journal:  Antimicrob Agents Chemother       Date:  2013-04-22       Impact factor: 5.191

7.  Interactions of Desmethoxyyangonin, a Secondary Metabolite from Renealmia alpinia, with Human Monoamine Oxidase-A and Oxidase-B.

Authors:  Narayan D Chaurasiya; Francisco León; Yuanqing Ding; Isabel Gómez-Betancur; Dora Benjumea; Larry A Walker; Stephen J Cutler; Babu L Tekwani
Journal:  Evid Based Complement Alternat Med       Date:  2017-08-24       Impact factor: 2.629

8.  Synthetic Kavalactone Analogues with Increased Potency and Selective Anthelmintic Activity against Larvae of Haemonchus contortus In Vitro.

Authors:  H M P Dilrukshi Herath; Aya C Taki; Nghi Nguyen; José Garcia-Bustos; Andreas Hofmann; Tao Wang; Guangxu Ma; Bill C H Chang; Abdul Jabbar; Brad E Sleebs; Robin B Gasser
Journal:  Molecules       Date:  2020-04-24       Impact factor: 4.411

9.  Kava for the treatment of generalised anxiety disorder (K-GAD): study protocol for a randomised controlled trial.

Authors:  Karen M Savage; Con K Stough; Gerard J Byrne; Andrew Scholey; Chad Bousman; Jenifer Murphy; Patricia Macdonald; Chao Suo; Matthew Hughes; Stuart Thomas; Rolf Teschke; Chengguo Xing; Jerome Sarris
Journal:  Trials       Date:  2015-11-02       Impact factor: 2.279

10.  Kavain, the Major Constituent of the Anxiolytic Kava Extract, Potentiates GABAA Receptors: Functional Characteristics and Molecular Mechanism.

Authors:  Han Chow Chua; Emilie T H Christensen; Kirsten Hoestgaard-Jensen; Leonny Y Hartiadi; Iqbal Ramzan; Anders A Jensen; Nathan L Absalom; Mary Chebib
Journal:  PLoS One       Date:  2016-06-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.